About Soliris®
Discovered, developed and marketed exclusively by Alexion, Soliris® (eculizumab) is the first
and only approved medication that blocks complement and reduces hemolysis in patients
with PNH.23 Clinical studies have found that Soliris improves the symptoms
and reduces the major health problems associated with PNH.18,19,24
In clinical trials
submitted to the U.S. Food and Drug Administration and other regulatory agencies
worldwide, patients who received Soliris experienced a number of benefits, including:
- Immediate and sustained reduction in chronic hemolysis in all patients18,19
- Fewer thrombotic events (blood clots) as compared to the same time period prior
to starting Soliris24
- Significant improvements in fatigue levels and overall quality of life18,19
- Significant reduction in the need for transfusions19
Alexion researchers and independent physicians continue to learn more about PNH
and its treatment through ongoing clinical experience and clinical studies.
Soliris is available in more than a dozen countries, including the United States,
Germany, the United Kingdom, France, Italy and Spain. In early 2009, regulatory
authorities in Australia and Canada approved Soliris for the treatment of patients
with PNH, and Alexion submitted an application for approval of Soliris in Japan.
Soliris is designated an orphan drug in the United States, European Union and other
territories.
“Soliris directly targets the underlying disease process responsible for debilitating
symptoms that may contribute to shortened life spans of PNH patients. Having cared
for more than 300 patients with PNH over my career, I believe this is the most important
advance that has been made in the treatment of this disease. Treatment with Soliris
markedly decreases the hemolysis responsible for anemia, fatigue, poor patient functioning
and blood clots in PNH patients.”
Wendell F. Rosse, M.D.
Florence McAlister Professor of Medicine Emeritus
Duke University
Hear more from Dr. Rosse at
PNHSource.com.